Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FERTINEX vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Follitropin beta, a recombinant form of human follicle-stimulating hormone (FSH), binds to the FSH receptor on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and maturation in women and spermatogenesis in men.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Ovulation induction in anovulatory women with polycystic ovary syndrome (PCOS) who have failed to respond to clomiphene citrate,Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF),Hypogonadotropic hypogonadism in men
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
For ovulation induction: 75-150 IU subcutaneously or intramuscularly once daily for 7-12 days; for spermatogenesis: 75-150 IU subcutaneously or intramuscularly 3 times per week.
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
Terminal elimination half-life is approximately 24-36 hours in patients with normal renal function, supporting once-daily dosing.
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
Metabolized primarily via the liver and kidneys; exact enzymes not fully characterized, but involves hepatic degradation and renal excretion.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Primarily renal excretion of unchanged drug (80-90% of administered dose), with the remainder excreted as metabolites in urine and feces.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 60-70% bound to plasma proteins, primarily albumin.
92% bound primarily to albumin
Vd is approximately 0.3-0.5 L/kg, indicating distribution mainly into extracellular fluid.
0.4 L/kg, indicating distribution primarily in extracellular fluid
Subcutaneous: ~70% relative to intravenous; intramuscular: ~90% relative to intravenous.
Oral: 85% with high first-pass effect; IM: 100%
No specific dosing guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data; consider reduced dose or extended interval.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
No specific dosing guidelines; use with caution in severe hepatic impairment (Child-Pugh class C) due to limited data; consider reduced dose.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
For delayed puberty (males): 75-150 IU subcutaneously or intramuscularly 3 times per week; adjust based on testosterone response. For cryptorchidism: 1000-1500 IU subcutaneously or intramuscularly 2-3 times per week for 4-6 weeks; not weight-based but age-adjusted.
Not approved for pediatric use.
Elderly patients are not typically candidates for FERTINEX; no specific dose adjustments recommended due to lack of use; monitor for comorbidities and potential hypersensitivity.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
FERTINEX should only be used by physicians with expertise in infertility treatment. Ovarian hyperstimulation syndrome (OHSS) may occur, which can be severe and result in ovarian enlargement, pelvic pain, ascites, pleural effusion, and thromboembolic events. Multiple gestation increases the risk of adverse maternal and perinatal outcomes.
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
Risk of ovarian hyperstimulation syndrome (OHSS), which may be severe and require hospitalization,Increased risk of multiple gestation (twins, triplets, etc.),Ovarian torsion reported,Potential for ovarian enlargement and cyst formation,Thromboembolic events, especially in patients with risk factors,Should not be used in patients with primary ovarian failure, uncontrolled thyroid/adrenal dysfunction, or sex hormone-dependent tumors
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
Pregnancy,Lactation,Primary ovarian failure (elevated FSH levels),Uncontrolled thyroid or adrenal dysfunction,Sex hormone-dependent tumors (e.g., breast, ovarian, uterine),Hypersensitivity to follitropin beta or any component of the formulation
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
No specific food interactions. Maintain a balanced diet rich in folic acid (400-800 mcg/day) to reduce risk of neural tube defects. Avoid excessive alcohol and caffeine.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
Fertinex (urofollitropin) is associated with a Category X risk in pregnancy. Administration during pregnancy may cause fetal harm, including congenital malformations (neural tube defects, limb defects) and spontaneous abortion. Use is contraindicated in pregnant women.
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
Safety during breastfeeding has not been established. Excretion in human milk is unknown; no M/P ratio available. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
No dose adjustments are indicated as Fertinex is contraindicated in pregnancy. Use should be discontinued if pregnancy is confirmed.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
FERTINEX (urofollitropin) is a purified FSH product used for ovulation induction. Monitor ovarian response via serum estradiol levels and transvaginal ultrasound to assess follicle size and number. Adjust dose based on response to minimize OHSS risk. Administer IM or SC after reconstitution. Use caution in patients at risk for thromboembolism.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
FERTINEX is a hormone injection given under the skin or into a muscle to help you ovulate.,You will need training on how to inject the medication and dispose of needles safely.,Common side effects include headache, bloating, and injection site reactions.,Seek immediate medical attention if you experience severe pelvic pain, sudden weight gain, or shortness of breath.,Avoid alcohol and limit caffeine intake during treatment.,Report any signs of ovarian hyperstimulation syndrome (OHSS) such as nausea, vomiting, or decreased urination.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FERTINEX vs ANTAGONATE, answered by our medical review team.
FERTINEX is a Gonadotropin that works by Follitropin beta, a recombinant form of human follicle-stimulating hormone (FSH), binds to the FSH receptor on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and maturation in women and spermatogenesis in men.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FERTINEX and ANTAGONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FERTINEX is: For ovulation induction: 75-150 IU subcutaneously or intramuscularly once daily for 7-12 days; for spermatogenesis: 75-150 IU subcutaneously or intramuscularly 3 times per week.. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FERTINEX and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FERTINEX is classified as Category C. Fertinex (urofollitropin) is associated with a Category X risk in pregnancy. Administration during pregnancy may cause fetal harm, including congenital malformations (neural tube d. ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.